Do BPC-157 and TB-500 work better together?

The rationale offered is that they act through different mechanisms, which is true. Whether the combination outperforms either alone has largely not been tested — the co-administration literature is thin.

Is Wolverine peptide one compound?

No. It names a pairing of two separate compounds, and the term itself carries no specification of sequence, purity or quantity.

BPC-157 (Pentadecapeptide)

Why BPC-157 and TB-500 Are Called the Wolverine Stack

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-313 cited sources

"Wolverine peptide" is informal shorthand for combining BPC-157 and TB-500, named after the comic character known for rapid healing. It is a marketing term, not a technical one: it describes a pairing, carries no specification, and the co-administration literature behind it is thin.

Key facts

What it names: BPC-157 plus TB-500
Origin: Comic character, not research
Technical standing: None
Co-administration studies: Sparse
Rationale offered: Different mechanisms

Where the name comes from

It is a reference to the Marvel character whose defining trait is healing rapidly from injury. The name attached itself to the BPC-157 and TB-500 pairing because both are studied in tissue repair contexts, and it spread through forums and vendor listings rather than through any literature. No paper uses it.

The two compounds are genuinely different

BPC-157 is a fifteen-residue sequence derived from a protein in gastric juice, studied mainly for tendon, ligament and gastrointestinal repair, with angiogenesis and growth factor signalling as proposed mechanisms. TB-500 is Ac-LKKTETQ, a seven-residue fragment of thymosin beta-4, studied for actin sequestration and cell migration. The stated rationale for pairing them is that they act through different routes, which is at least true.

Research material referenced

BPC-157 5mg — third-party HPLC tested

View — £15.99

What the co-administration evidence actually is

Thin. Each compound has its own rodent literature; studies giving both together and measuring whether the combination outperforms either alone are far scarcer. The pairing is a plausible hypothesis that has largely not been tested, and a term that sounds like a finding is doing a lot of work to obscure that.

What the name obscures

A nickname carries no specification. It says nothing about sequence, purity, quantity or which fragment is in the vial — and the TB-500 half is a compound routinely confused with the full thymosin beta-4 protein it derives from. Anyone evaluating material sold under this name is better served by the certificate than by the branding.

And this is laboratory material

Both compounds are supplied for laboratory research and neither holds a marketing authorisation anywhere. The rodent findings above describe experiments, not use in people.

Extended research context

The BPC-157 (Pentadecapeptide) deep dive

Deep dive: the pentadecapeptide sequence

BPC-157 is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is derived from a fragment identified in human gastric juice by the Zagreb research group (Sikirić and colleagues), whose body of published work spans three decades and covers models ranging from tendon repair to gut integrity. The 'BPC' initials stand for 'body protection compound' — the group's original characterisation term.

Two forms: acetate salt vs arginate

BPC-157 is supplied most commonly as an acetate salt; a small subset of suppliers offer the arginate form, which has slightly different solubility and stability properties. For research reproducibility, keep the salt form consistent across a study and confirm which form the CoA specifies (mass ± counterion changes the reading).

Reading a BPC-157 CoA

A trustworthy BPC-157 CoA lists HPLC purity (target ≥98% area), mass-spec confirmation (~1,419 Da for the free peptide), water content (Karl Fischer), acetate content, and residual solvents. Some batches also include endotoxin data. Any missing category is a red flag for a compromised supply chain.

Research applications

▸Cell-culture models of gut epithelial integrity
▸Tendon fibroblast migration and collagen-synthesis assays
▸Angiogenesis models involving VEGF and NO signalling
▸Stability studies comparing acetate vs arginate salt forms
▸Analytical reference for pentadecapeptide HPLC methods

Handling checklist

✓Store lyophilised vial at −20 °C long-term (2–8 °C short-term)
✓Reconstitute with bacteriostatic water; a 5 mg vial dissolves cleanly
✓Aliquot reconstituted solution; keep refrigerated 2–8 °C, use within 28 days
✓Protect from light and repeated warming
✓Verify CoA: HPLC ≥98%, mass ~1,419 Da, salt form declared

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Mixing acetate and arginate BPC-157 across a study

Fix: Choose one salt form and stay with it — different masses and solubility.

✗ Assuming stability at room temperature

Fix: Refrigerate reconstituted solution; discard after 28 days.

✗ Buying without a CoA

Fix: Only source from suppliers that publish batch HPLC + mass-spec data.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

What is the Wolverine peptide?: Informal shorthand for combining BPC-157 and TB-500, named after the comic character known for rapid healing. It is a marketing term with no technical standing.
Do BPC-157 and TB-500 work better together?: The rationale offered is that they act through different mechanisms, which is true. Whether the combination outperforms either alone has largely not been tested — the co-administration literature is thin.
Is Wolverine peptide one compound?: No. It names a pairing of two separate compounds, and the term itself carries no specification of sequence, purity or quantity.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More BPC-157 (Pentadecapeptide) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum